Abstract | BACKGROUND/OBJECTIVE: PATIENTS AND METHODS: Nine patients with PsA and 14 with RA received RTX at 1000 mg twice within 14 days and were evaluated over 6 months. RESULTS: A PsA response criteria response was attained in 56% of patients. DAS28 improved from 6.2 to 4.9 (medians) in PsA and 6.4 to 5.2 in RA, and Health Assessment Questionnaire from 1.5 to 1.0 and from 2.1 to 1.4, respectively (all p≤0.05). Disease Activity index for PSoriatic Arthritis changed from 52.0 to 32.5 (p<0.05); C reactive protein and Psoriasis Area and Severity Index did not change significantly. RTX was tolerated well. CONCLUSIONS: In this exploratory open study, RTX exhibited significant efficacy in PsA patients with long-standing disease. Thus, RTX may have efficacy in PsA warranting a randomised controlled clinical trial.
|
Authors | Esther Jimenez-Boj, Tanja A Stamm, Martina Sadlonova, Jozef Rovensky, Helena Raffayová, Burkhard Leeb, Klaus Peter Machold, Winfried B Graninger, Josef S Smolen |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 71
Issue 11
Pg. 1868-71
(Nov 2012)
ISSN: 1468-2060 [Electronic] England |
PMID | 22833373
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Antirheumatic Agents
- Rituximab
|
Topics |
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Psoriatic
(drug therapy, pathology, physiopathology)
- Female
- Humans
- Hyperalgesia
(drug therapy, pathology, physiopathology)
- Joints
(drug effects, pathology, physiopathology)
- Male
- Middle Aged
- Pilot Projects
- Rituximab
- Treatment Outcome
|